PUBLISHER: KuicK Research | PRODUCT CODE: 1807074
PUBLISHER: KuicK Research | PRODUCT CODE: 1807074
Global Peptide Cancer Vaccine Market Opportunity, Technology Platforms & Clinical Trials Insight 2030
Global Peptide Cancer Vaccine Market Opportunity, Technology Platforms & Clinical Trials Insight 2030 Report findings & Highlights:
- Global & Regional Market Trends Insight
- Peptide Cancer Vaccine Classification By Source, Length & Epitope Specificity
- Peptide Cancer Vaccines In Clinical Trials: > 50 Vaccines
- US Dominating Peptide Cancer Vaccines Development Landscape: > 20 Vaccines
- Global Peptide Cancer Vaccine Clinical Trials Insight By Company, Country, Phase & Indication
- Insight On Peptide Cancer Vaccine Development Technology Platforms By Companies
- Completive Landscape
Peptide Cancer Vaccine Need & Why This Report?
Cancer remains among the most common causes of death globally, and current therapies like chemotherapy and radiation are frequently associated with serious side effects and inconsistent response rates. In such an instance, peptide based cancer vaccines could offer a viable option for targeted immune mediated cancer destruction with less toxicity. Such vaccines utilize tumor specific or neoantigenic peptides to generate extremely specific T-cell responses with the precision of immunotherapy without the intricacy of cell or viral vector platforms.
This report is aimed at filling an expanding market need by delivering stakeholders, including biotech firms, investors, healthcare planners, and regulators, with practical insights into the dynamic cancer peptide vaccine market. With a number of candidates undergoing clinical trials and nearing commercialization, insight into the current situation and future direction is necessary for intelligent decision making.
Clinical Trials Insight Included In Report
The report delivers in-depth information from more than 50 ongoing and completed clinical trials from all over the globe. It provides a breakdown of the pipeline by trial phase, cancer type, therapeutic target, and combination regimen, as well as sponsors, collaborators, technology licensors, and geographic regions. Interestingly, there is heightened interest in multivalent vaccines acting on several epitopes as well as peptide vaccines under investigation with checkpoint inhibitors.
Among the late stage clinical contenders, SELLAS Life Sciences' Galinpepimut-S is in a Phase III trial for AML and has also been active in mesothelioma. Other ongoing trials involve peptide vaccines in NSCLC, prostate cancer, triple-negative breast cancer, and glioblastoma. The trials cover a number of geographies, such as the US, EU, Japan, China, and South Korea, highlighting the international appeal of peptide vaccine platforms.
Leading Companies Engaged In R&D Of Peptide Cancer Vaccine
There are numerous biotechnology companies as well as pharmaceutical firms that are developing peptide based immunotherapy pipelines. Some of the key players are Scancell Holdings, SELLAS Life Sciences, ISA Pharmaceuticals, Imugene, and BrightPath Biotherapeutics. They are all working on both monovalent and polyvalent vaccine strategies.
Every firm has its own distinct approach; some aim at common tumor antigens, whereas others design customized neoantigen vaccines based on next-generation sequencing results. Then there are participants such as OncoTherapy Science and VAXON Biotech that are creating cancer-specific pipelines, in general, aimed at antigens such as WT1, MAGE-A3, or survivin.
Technology Platforms, Collaborations & Agreements
The peptide cancer vaccine market is more and more influenced by cutting-edge technology platforms and strategic partnerships. Exclusive platforms like Moditope(R) (Scancell) and T-win(R) (IO Biotech) are the main differentiators that improve immunogenicity and delivery efficacy. Such platforms allow improved epitope presentation, activation of immune cells, and minimizing the risk of immune escape.
Collaborations are now essential to the advancement of pipelines. Numerous companies are entering co-development deals with CDMOs, academic institutions, or bigger pharma partners. For instance, SELLAS has collaborated with Memorial Sloan Kettering for its GPS vaccine, and various companies are collaborating with regional manufacturing partners in Europe and Asia for ramping up GMP production. Licensing deals are also increasing, allowing the exchange of peptide libraries and immunoinformatics tools among partners.
Report Indicating Future Direction Of Peptide Cancer Vaccine Segment
The report suggests a very promising but competitive future for cancer peptide vaccines. Although Riavax is currently the sole peptide vaccine that has obtained market approval in South Korea, which was subsequently withdrawn, it demonstrated the validity of the concept. The science has developed considerably since, however, with enhanced antigen discovery, more efficient stratification of patients, and a move towards combination forms of therapy.
The destiny of this space will most probably be controlled by multiepitope vaccines and neoantigen personalization enabled by AI and big data analysis. Commercial interest is likely to increase in unmet need indications like glioblastoma, pancreatic cancer, and refractory NSCLC. With regulatory agencies offering clearer guidelines for immunotherapy approvals and integration of real-world data, some late-stage peptide vaccines may receive approvals in the next 3-5 years.
This report is a must read for stakeholders looking to ride the increasing tide in this space, providing data-driven insights on innovation trends, trial updates, collaborations, and commercialization channels in the landscape of peptide cancer vaccines.
Table of Contents
1. Introduction To Peptide Cancer Vaccines
- 1.1 Overview & Historical Context
- 1.2 Peptide Based Immunotherapy In Oncology
2. Need For Peptide Cancer Vaccines
- 2.1 Why Peptides Are More Desirable In Cancer Immunotherapy
- 2.2 Peptide Vaccines vs. Traditional Cancer Vaccines
- 2.3 Gaps Addressed By Peptide Vaccines
3. Peptide Cancer Vaccines Mechanism Of Action
4. Classification Of Peptide Cancer Vaccines
- 4.1 Based On Source Of Peptides
- 4.2 Based on Peptide Length
- 4.3 Based on Epitope Specificity
5. Peptide Cancer Vaccines Development & Clinical Trends By Indication
- 5.1 Brain Cancer
- 5.2 Breast Cancer
- 5.3 Lung Cancer
- 5.4 Skin Cancers
- 5.5 Gastrointestinal Cancers
- 5.6 Gynecologic Cancers
6. Global Peptide Cancer Vaccine Market Overview
- 6.1 Current Market Landscape
- 6.2 Future Outlook & Innovation Opportunities
7. Global Peptide Cancer Vaccine Market Development Trends By Region
- 7.1 US
- 7.2 Europe
- 7.3 China
- 7.4 Japan
- 7.5 South Korea
8. Global Peptide Cancer Vaccine Pipeline Overview
- 8.1 By Country
- 8.2 By Company
- 8.3 By Indication
- 8.4 By Phase
9. Global Peptide Cancer Vaccine Clinical Trials Insight By Company, Country, Phase & Indication
- 9.1 Preclinical
- 9.2 Phase-I
- 9.3 Phase-I/II
- 9.4 Phase-II
- 9.5 Phase-III
10. Global Peptide Cancer Vaccine Market Dynamics
- 10.1 Key Drivers & Opportunities
- 10.2 Market Challenges & Limitations
11. Technology Platforms For Peptide Cancer Vaccine Development By Companies
12. Competitive Landscape
- 12.1 3D Medicines
- 12.2 BrightPath Biotherapeutics
- 12.3 Circio Holding
- 12.4 Cecava
- 12.5 Dx&Vx
- 12.6 Elicio
- 12.7 Evaxion
- 12.8 GemVax & KAEL
- 12.9 IO Biotech
- 12.10 ISA Pharmaceuticals
- 12.11 OncoTherapy Science
- 12.12 OSE Immunotherapeutics
- 12.13 Nouscom
- 12.14 Nykode Therapeutics
- 12.15 Scancell
- 12.16 SELLAS Life Sciences
- 12.17 Seqker Biosciences
- 12.18 Shionogi
- 12.19 Vaxon Biotech
- 12.20 Zelluna
List of Figures
- Figure 1-1: Peptide Cancer Vaccine Development - Key Milestones
- Figure 1-2: Personalized Peptide Vaccines Based On Neoantigens
- Figure 1-3: Peptide-Based Cancer Immunotherapy Mechanism
- Figure 1-4: Dual Pathway Activation Via Peptides
- Figure 1-5: Peptide Delivery Technologies
- Figure 1-6: Peptide Combination Therapies
- Figure 1-7: Peptide Immunotherapy - Challenges vs Solutions
- Figure 2-1: Benefits of Peptides in Immunotherapy
- Figure 2-2: Tumor Types & Peptide Targets
- Figure 2-3: Multifunctional Peptides In Immunotherapy
- Figure 2-4: Peptide-Based Immunotherapies In Global Health
- Figure 2-5: Antigen Loss & Immune Escape vs Multi-Epitope Vaccination
- Figure 3 1: Peptide Cancer Vaccines - Mechanism Of Action
- Figure 4-1: Tumor-Associated Antigen Sources
- Figure 4-2: Neoantigen Generation Sources
- Figure 4-3: Tumor-Associated Antigen vs. Tumor-Specific Antigen-Derived Peptide Vaccines - Microenvironment Impact
- Figure 4-4: Short Peptides - Pros & Cons
- Figure 4-5: Long Peptides - Pros & Cons
- Figure 4-6: Short & Long Peptide Vaccines - Antigen Processing & Presentation Pathways
- Figure 4-7: CD8+ T Cell Activation Functional Outcomes
- Figure 4-8: CD4+ T Cell Activation Functional Outcomes
- Figure 4-9: MHC Class I & II - Antigen Processing Pathways
- Figure 5-1: SURVIVE Phase II (NCT05163080) Study - Initiation & Estimated Completion Year
- Figure 5-2: NCI-2015-00694 Phase II (NCT02455557) Study - Initiation & Estimated Completion Year
- Figure 5-3: CONNECT1906 Phase II (NCT05096481) Study - Initiation & Estimated Completion Year
- Figure 5-4: PRO13110086 Phase II (NCT02358187) Study - Initiation & Estimated Completion Year
- Figure 5-5: PRO12050422 Phase I (NCT01795313) Study - Initiation & Estimated Completion Year
- Figure 5-6: FLAMINGO-01 Phase III (NCT05232916) Study - Initiation & Estimated Completion Year
- Figure 5-7: Pro00104868 Phase I (NCT04270149) Study - Initiation & Estimated Completion Year
- Figure 5-8: CTO-IUSCCC-09138 Phase I (NCT06414733) Study - Initiation & Estimated Completion Year
- Figure 5-9: 16-132 Phase I (NCT02826434) Study - Initiation & Estimated Completion Year
- Figure 5-10: NCI-2016-01878 Phase II (NCT03012100) Study - Initiation & Estimated Completion Year
- Figure 5-11: ARTEMIA Phase III (NCT06472245) Study - Initiation & Estimated Completion Year
- Figure 5-12: PNeoVCA Phase I/II (NCT05269381) Study - Initiation & Estimated Completion Year
- Figure 5-13: J23120 Phase I/II (NCT05950139) Study - Initiation & Estimated Completion Year
- Figure 5-14: AMPLIFY-201 Phase I (NCT04853017) Study - Initiation & Estimated Completion Year
- Figure 5-15: 18-279 Phase I (NCT03929029) Study - Initiation & Estimated Completion Year
- Figure 5-16: KEYNOTE-D18 Phase III (NCT05155254) Study - Initiation & Estimated Completion Year
- Figure 5-17: AMPLIFY-7P Phase I/II (NCT05726864) Study - Initiation & Estimated Completion Year
- Figure 5-18: OBERTO-301 Phase II (NCT05243862) Study - Initiation & Estimated Completion Year
- Figure 5-19: TEDOPAM Phase II (NCT03806309) Study - Initiation & Estimated Completion Year
- Figure 5-20: GO-010 Phase II/III (NCT05141721) Study - Initiation & Estimated Completion Year
- Figure 5-21: AMC-099 Phase III (NCT03284866) Study - Initiation & Estimated Completion Year
- Figure 5-22: SAHoWMU-CR2024-07-107 Phase II/III (NCT06341907) Study - Initiation & Estimated Completion Year
- Figure 5-23: GINECO-OV244b Phase II (NCT04713514) Study - Initiation & Estimated Completion Year
- Figure 6-1: Global Cancer Peptide Vaccine Market - Future Opportunities
- Figure 8-1: Global - Peptide Cancer Vaccine in Clinical Pipeline by Country, 2025 Till 2030
- Figure 8-2: Global - Peptide Cancer Vaccine in Clinical Pipeline by Company, 2025 Till 2030
- Figure 8-3: Global - Peptide Cancer Vaccine in Clinical Pipeline by Indication, 2025 Till 2030
- Figure 8-4: Global - Peptide Cancer Vaccine in Clinical Pipeline by Phase, 2025 Till 2030
- Figure 10-1: Global Cancer Peptide Vaccine Market - Market Drivers & Opportunities
- Figure 10-2: Global Cancer Peptide Vaccine Market - Market Challenges & Limitations
- Figure 11-1: Cecava - Personalized Neoepitope Peptide Vaccine Platform
- Figure 11-2: IO Biotech - T-win
- Figure 11-3: ISA Pharmaceuticals - SLP Technology
List of Tables
- Table 2-1: Peptide Vaccines vs. Traditional Cancer Vaccines
- Table 2-2: Gaps In Cancer Treatment Addressed By Peptide Vaccines
- Table 4-1: Tumor-Associated Antigen vs. Tumor-Specific Antigen-Derived Peptide Vaccines
- Table 4-2: Short vs Long Peptide Vaccines
- Table 4-3: Short vs Long Peptide Vaccines - Ideal Candidate Use Scenarios
- Table 4-4: MHC Class I vs MHC Class II Peptide Vaccines
- Table 4-5: MHC-I & MHC-II Vaccines - Unique & Overlapping Features
